Karyopharm Therapeutics
KPTI
113 hedge funds and large institutions have $113M invested in Karyopharm Therapeutics in 2024 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 36 increasing their positions, 31 reducing their positions, and 22 closing their positions.
76% more capital invested
Capital invested by funds: $64.2M → $113M (+$48.7M)
16% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 31
3% more call options, than puts
Call options by funds: $330K | Put options by funds: $321K
0.01% more ownership
Funds ownership: 4.33% → 4.33% (+0.01%)
9% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 22
3% less funds holding
Funds holding: 117 → 113 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EP
Eversept Partners
New York
|
+$5.86M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$2.15M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$782K |
| 4 |
D.E. Shaw & Co
New York
|
+$404K |
| 5 |
State Street
Boston,
Massachusetts
|
+$271K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.63M |
| 2 |
Renaissance Technologies
New York
|
-$1.24M |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$1.21M |
| 4 |
TC
Tejara Capital
London,
United Kingdom
|
-$892K |
| 5 |
BlackRock
New York
|
-$729K |
KPTI Hedge Fund Activity: Q1 2024 in Review
113 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q1 2024, worth a combined $113M — up 76% from $64.2M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of KPTI and 20 opened new positions — a net loss of 2 holders — while 31 trimmed existing stakes and 36 added.
The largest buyer was Eversept Partners, opening a new position worth an estimated $5.86M. The largest seller was Morgan Stanley, cutting an estimated $1.63M.
- 113 institutional investors held Karyopharm Therapeutics (KPTI) as of Q1 2024, down from 117 in Q4 2023.
- Funds reported $113M of Karyopharm Therapeutics stock for Q1 2024, up 76% quarter-over-quarter.
- 20 funds opened new Karyopharm Therapeutics positions in Q1 2024 and 22 closed out, a net change of -2 holders.
- The largest Karyopharm Therapeutics buyer in Q1 2024 was Eversept Partners, an estimated $5.86M added.
- The largest Karyopharm Therapeutics seller in Q1 2024 was Morgan Stanley, an estimated $1.63M sold.
Based on aggregated 13F filings for Q1 2024.